Nicotine Therapy for Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 40868069 · doi:10.3390/biomedicines13081814
What was done
Authors systematically searched PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs) evaluating nicotine therapy administered for more than 1 week in patients with Parkinson's disease. Standardized mean differences (SMDs) for motor and nonmotor outcomes were pooled using random-effects models for short-term (<6 months) and long-term (≥6 months) durations.
What was found
Across 5 RCTs with 346 participants, nicotine therapy produced no significant improvement in short-term motor outcomes (pooled SMD: -0.452, 95% CI: -1.612 to 0.708) or long-term motor outcomes (pooled SMD: 0.174, 95% CI: -0.438 to 0.787). Interstudy heterogeneity was considerable. Short-term treatment also failed to significantly improve daily functioning, cognition, or quality of life.
Why it matters
Despite strong epidemiological associations between tobacco use and reduced Parkinson's disease risk, this synthesis shows nicotine does not translate into clinical efficacy for established motor or nonmotor symptoms.
Limits
The analysis is constrained by a small total sample size (5 trials, 346 patients) and notable heterogeneity across studies. Specific formulations, doses, and disease stages were not detailed in the abstract.
Cited by
- context Over 50 studies indicate that nicotine users have a 60% lower risk of developing Parkinson's disease.